Cullinan Therapeutics to Participate in Upcoming Investor Conferences

About this update from Cullinan Therapeutics, Inc.

[{"type":"image","alt":"Cullinan Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Cullinan Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/af7bcb98ff1045bf2445c3cd8a062e05"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kuI0MWklffj9jltO0FlcBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/af7bcb98ff1045bf2445c3cd8a062e05","width":300,"height":157}},"lazy":false},{"type":"text","content":"CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its participation in the following upcoming investor conferences:","length":282,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 in New York, NY on Thursday, September 4, 2025, at 2:10 p.m. ET.","length":242,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":242,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY on September 10, 2025, at 8:30 a.m. ET.","length":248,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":248,"olType":false},{"type":"text","content":"Webcasts of the fireside chats will be available under the Events and Presentations section of the Company’s investor relations website at https://investors.cullinantherapeutics.com/events.","length":194,"tagName":"p"},{"type":"text","content":"About Cullinan Therapeutics","length":27,"tagName":"p"},{"type":"text","content":"Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullina...

More updates from Cullinan Therapeutics, Inc.